Long-acting beta2-agonists for maintenance therapy of stable chronic obstructive pulmonary disease: a systematic review

Shukla VK, Husereau DR, Boucher M, Mensinkai S, Dales R
Record ID 32002000901
English, French
Authors' objectives:

This report aims to determine, through a systematic review of the literature, the efficacy and safety of salmeterol and formoterol for patients with stable non-reversible chronic obstructive pulmonary disease (COPD) as compared to: - placebo with or without the additional use of short-acting beta2-agonists; and - anticholinergics with or without the additional use of short-acting beta2-agonists

For the purpose of this assessment, COPD was considered stable if there had been no infections, flare-ups or hospitalizations in the past month.

Authors' recommendations: The review found that, compared to placebo, the long-acting beta2-agonists are superior in decreasing the use of rescue inhalers. However, they did not improve functional outcomes, such as distance travelled in a six-minute walk test. Two reports identified in the literature search compared the efficacy of long-acting beta2-agonists with ipratropium bromide. Neither report showed salmeterol or formoterol to be more efficacious in the patient group studied.
Authors' methods: Systematic review
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 2002
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Bronchodilator Agents
  • Pulmonary Disease, Chronic Obstructive
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.